Morgan Stanley’s Monopar Therapeutics MNPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.22M | Sell |
22,312
-4,655
| -17% | -$281K | ﹤0.01% | 5040 |
|
|
2025
Q4 | $1.76M | Buy |
26,967
+11,256
| +72% | +$920K | ﹤0.01% | 4898 |
|
|
2025
Q3 | $1.28M | Buy |
15,711
+7,779
| +98% | +$348K | ﹤0.01% | 5042 |
|
|
2025
Q2 | $284K | Buy |
7,932
+6,508
| +457% | +$236K | ﹤0.01% | 5712 |
|
|
2025
Q1 | $51.8K | Sell |
1,424
-2,377
| -63% | -$85.7K | ﹤0.01% | 6254 |
|
|
2024
Q4 | $83.6K | Buy |
+3,801
| New | +$63.8K | ﹤0.01% | 6127 |
|
|
2024
Q2 | – | Sell |
-160
| Closed | -$545 | – | 7925 |
|
|
2024
Q1 | $545 | Sell |
160
-160
| -50% | -$477 | ﹤0.01% | 7233 |
|
|
2023
Q4 | $544 | Buy |
320
+160
| +100% | +$324 | ﹤0.01% | 7274 |
|
|
2023
Q3 | $496 | Sell |
160
-640
| -80% | -$2.24K | ﹤0.01% | 7308 |
|
|
2023
Q2 | $3.42K | Hold |
800
| – | – | ﹤0.01% | 7068 |
|
|
2023
Q1 | $5.56K | Hold |
800
| – | – | ﹤0.01% | 7026 |
|
|
2022
Q4 | $9.48K | Hold |
800
| – | – | ﹤0.01% | 6957 |
|
|
2022
Q3 | $6K | Hold |
800
| – | – | ﹤0.01% | 7210 |
|
|
2022
Q2 | $9K | Sell |
800
-1
| -0.1% | -$11 | ﹤0.01% | 7247 |
|
|
2022
Q1 | $10K | Buy |
801
+1
| +0.1% | +$15 | ﹤0.01% | 7402 |
|
|
2021
Q4 | $13K | Hold |
800
| – | – | ﹤0.01% | 7381 |
|
|
2021
Q3 | $19K | Hold |
800
| – | – | ﹤0.01% | 7117 |
|
|
2021
Q2 | $24K | Buy |
800
+160
| +25% | +$4.58K | ﹤0.01% | 6944 |
|
|
2021
Q1 | $20K | Hold |
640
| – | – | ﹤0.01% | 6717 |
|
|
2020
Q4 | $20K | Hold |
640
| – | – | ﹤0.01% | 6435 |
|
|
2020
Q3 | $17K | Hold |
640
| – | – | ﹤0.01% | 6116 |
|
|
2020
Q2 | $24K | Hold |
640
| – | – | ﹤0.01% | 5961 |
|
|
2020
Q1 | $23K | Sell |
640
-1,486
| -70% | -$93K | ﹤0.01% | 5757 |
|
|
2019
Q4 | $177K | Buy |
+2,126
| New | +$222K | ﹤0.01% | 5460 |
|
Other funds holding MNPR
RCM
SVCM
DM
SL
ACM
PCH
VCM